Reading time is 1 mins
.
.
BLACK FUNGUS VIRUS DOES NOT STOP TILL IT FINDS A NEW VICTIM
In India, which has become one of the epicenters of the corona virus outbreak, the nightmare does not end… It was announced that more than 45 thousand people across the country were infected with black fungus (mukormikoza). The disease, which causes eye loss, has been seen in India, as well as Afghanistan and Egypt.
As the corona virus, which began in China in the last days of 2019, mutated and continued to spread all over the world, a new epidemic emerged that caused concern to the international public.
.
50 PERCENT LETHALITY
In India, which has become one of the epicenters of the corona virus epidemic, survivors of Covid-19 are now also battling the black fungus (mukormikoza) disease. It was announced that 85 percent of those fighting the black fungus, which has infected more than 45,000 people across the country, are people who have survived Covid-19.
It also said 4,300 people died from black fungus disease, a lung infection. US-based media outlet CNN quoted what happened in India, which is grappling with the black fungus disaster. He said that the death rate of black fungus disease, seen in people whose immunity has fallen due to the corona virus, is 50 percent.
.
DETECTED IN MANY COUNTRIES
Many patients can even have their eyes removed to get rid of the disease, which causes black fungus spots, vision loss and death. According to official data, the disease has been seen in India, as well as Nepal, Afghanistan, Egypt and Oman.
A man named Harr told CNN that diabetics have a high risk of developing the disease. The man, who could not give his last name, said: “I was relieved after getting past Covid-19. I thought Covid-19 was the worst. But then I got a pain in my left eye. I couldn’t even open my eyes, the pain was too high. In the following days, blood began to flow from my eyes and nose. I went to the hospital and they took infected tissue and parts,” he said.
.
.
.
.
.
Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.
Physician's Resume:
Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.
Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.
In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.
Awards:
Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.
Certificates:
Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .
Professional Members:
American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.
Disclaimer:
Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.